Table 3 LPS protocol characteristics per compound.

From: Comparison of luteal support protocols in fresh IVF/ICSI cycles: a network meta-analysis

Part of Intervention

Compound

Brand name

Route

Dose (Median)

Dose (Max)

Median start of treatment

Median start of treatment SD (days)

Median end of treatment (Weeks)

Median SD end of Treatment (weeks)

Total Number of Patients

VP; IM + VP; VP + OE; VP + PatchE; IMP + VP + OE; IMP + VE; VP + SCGNRH; VP + DHEA; IMP + VP + SCGNRH; OP + VP; SCP + VP

Progesterone (Gel)

Crinone 8%

PV

90 mg

270 mg

OPU

1

10

3

9398

Progesterone (Pessary)

Utrogestan; Cyclogest; Endometrin; Progeffik;Progestan; Prontogest

PV

600 mg

800 mg

OPU

1.5

8

4

11,033

VP

Progesterone (Ring)

-

PV

1000 mg

1000 mg

OPU

1

7

2.5

1540

OP; OP + VP

Progesterone (Tablet)

Duphaston; Utrogestan

O

Duphaston 30 mg; Utrogestan 600 mg

Duphaston 40 mg; Utrogestan 600 mg

OPU

2

12

3.5

3785

RP

Progesterone (Pessary)

Cyclogest

PR

600 mg

800 mg

OPU

0

4

2

168

SCP

Progesterone (Solution)

Prolutex

SC

25 mg

50 mg

OPU

0

10

2

955

IM + VP; IMP + OE; IMP + VP + OE; IMP + VP + OE; IMP + VE; IMP + VP + SCGNRH

Progesterone (Solution)

Progesterone oil; Gestone

IM

100 mg

200 mg

OPU

1

6

3.5

5134

VP + OE; IMP + VP + OE; VP + OE + SCGNRH

Estradiol valerate

Estrofem; Progynova; Cycloprogynova (with norgestrel)

O

4 mg

4 mg

OPU

1

7

4

1920

IMP + IME

Estradiol valerate

Estradiol valerate

IM

20 mg

20 mg

OPU

0

12

0

55

IMP + VE

Estradiol valerate

Estradiol valerate

PV

4 mg

6 mg

OPU

2

6

0

174

VP + PatchE

Estradiol

Estraderm T

Patch

100 mcg

200 mcg

OPU

2

10

1.5

179

IMHCG

HCG

Pregnyl

IM

2000 IU

2500 IU

OPU + 2

2

2

1.2

592

SCHCG

HCG

Profasi

SC

1500 IU

1500 IU

OPU + 2

0

1

0

160

VP + SCGNRH; VP + OE + SCGNRH; IMP + VP + SCGNRH

GnRH

Decapeptyl; Leuprolide acetate; Triptorelin

SC

Decapeptyl 0.1 mg Leuprolide 1 mg Triptorelin 0.1 mg

Decapeptyl 0.1 mg Leuprolide 2 mg Triptorelin 0.1 mg

OPU

0

1 dose

14 doses (daily till bHCG test)

1607

Intranasal GNRG

GnRH

Buserelin

Intranasal

100mcg

200mcg

Ovulation trigger day

0

100 μg IN buserelin TDS for luteal support starting the next day of ovulation trigger up to day 14 of luteal phase

N/A

23

VP + DHEA

DHEA (tablets)

Prasterone

O

75 mg

75 mg

OPU

0

12

0

104

  1. Compound mono- or multi-treatment for luteal support, median and maximum dose, median day of luteal support initiation and median duration of treatment.
  2. OPU, Oocyte retrieval day; ET, Embryo Transfer; placebo, no exposure; SCP, Subcutaneous progesterone; VP, vaginal progesterone; IMP + VP, intramuscular progesterone and vaginal progesterone; VP + OE, vaginal progesterone and oral estradiol; IMP, intramuscular progesterone; VP + PatchE, vaginal progesterone and patch oestrogen; IMP + OE, intramuscular progesterone and oral estradiol; IMHCG, intramuscular hCG; SCP + VP, Intranasal GnRH-a; OP, oral progesterone; IMP + IME, intramuscular progesterone and intramuscular estradiol; IMP + VP + OE, Intramuscular progesterone, vaginal progesterone and oral estradiol; IMP + VE, Intramuscular progesterone and vaginal estradiol; VP + SCGNRH-a, Vaginal progesterone and subcutaneous GNRH agonist (GNRH-a); VP + OE + SCGNRH-a, Vaginal progesterone, oral estradiol and subcutaneous GNRH-a; RP, Rectal progesterone), SCHCG (subcutaneous HCG), VP + DHEA (vaginal progesterone and oral DHEA; IMP + VP + SCGNRH-a, Intramuscular progesterone, vaginal progesterone and subcutaneous GNRH-a; OP + VP, oral progesterone and vaginal progesterone.
Back to article page